- Home
- PEPG vs DXR Comparison
PEPG vs DXR Comparison
Compare PEPG & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEPG
- DXR
- Stock Information
- Founded
- PEPG 2018
- DXR 1970
- Country
- PEPG United States
- DXR United States
- Employees
- PEPG N/A
- DXR N/A
- Industry
- PEPG Biotechnology: Pharmaceutical Preparations
- DXR Medical/Dental Instruments
- Sector
- PEPG Health Care
- DXR Health Care
- Exchange
- PEPG Nasdaq
- DXR Nasdaq
- Market Cap
- PEPG 45.9M
- DXR 46.9M
- IPO Year
- PEPG 2022
- DXR N/A
- Fundamental
- Price
- PEPG $1.87
- DXR $11.42
- Analyst Decision
- PEPG Buy
- DXR Strong Buy
- Analyst Count
- PEPG 4
- DXR 1
- Target Price
- PEPG $7.25
- DXR $25.00
- AVG Volume (30 Days)
- PEPG 539.9K
- DXR 6.8K
- Earning Date
- PEPG 11-06-2025
- DXR 01-01-0001
- Dividend Yield
- PEPG N/A
- DXR N/A
- EPS Growth
- PEPG N/A
- DXR 3.46
- EPS
- PEPG N/A
- DXR 0.36
- Revenue
- PEPG N/A
- DXR $66,306.00
- Revenue This Year
- PEPG N/A
- DXR N/A
- Revenue Next Year
- PEPG N/A
- DXR N/A
- P/E Ratio
- PEPG N/A
- DXR $31.70
- Revenue Growth
- PEPG N/A
- DXR N/A
- 52 Week Low
- PEPG $0.88
- DXR $6.55
- 52 Week High
- PEPG $10.06
- DXR $11.70
- Technical
- Relative Strength Index (RSI)
- PEPG 71.39
- DXR 56.80
- Support Level
- PEPG $1.35
- DXR $11.37
- Resistance Level
- PEPG $2.10
- DXR $11.70
- Average True Range (ATR)
- PEPG 0.17
- DXR 0.50
- MACD
- PEPG 0.06
- DXR -0.00
- Stochastic Oscillator
- PEPG 76.29
- DXR 83.53
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.